Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders

被引:15
作者
Shah, Pranav [1 ]
Lalan, Manisha [2 ]
Barve, Kalyani [3 ]
机构
[1] Uka Tarsadia Univ, Maliba Pharm Coll, Surat, India
[2] Sat Kaival Coll Pharm, Sarsa, India
[3] SVKMs Narsee Monjee Inst Management Studies, Shobhaben Pratapbhai Patel Sch Pharm & Technol Man, Mumbai, Maharashtra, India
关键词
CNS disorders; drug delivery; nasal route; regulatory challenges; toxicity; nucleic acid; nucleic acid based therapeutics; CHALLENGING CLINICAL TRANSLATION; TO-BRAIN DELIVERY; PLASMID DNA; ANTISENSE OLIGONUCLEOTIDES; TRANSNASAL DELIVERY; NASAL DELIVERY; SIRNA; NANOPARTICLES; GEMCITABINE; THERAPY;
D O I
10.3389/fphar.2022.974666
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The etiologies of several cardiovascular, inflammatory, neurological, hereditary disorders, cancer, and infectious diseases have implicated changes in the genetic set up or genetic mutations as the root cause. Nucleic acid based therapeutics (NBTs) is a new class of biologics that are known to regulate gene expression at the transcriptional and post-transcriptional level. The NBTs include oligonucleotides, nucleosides, antisense RNA, small interfering RNAs, micro RNA etc. In recent times, this new category of biologics has found enormous potential in the management of cardiovascular, inflammatory, neurological disorders, cancer, infectious diseases and organ transplantation. However, the delivery of NBTs is highly challenging in terms of target specificity (intracellular delivery), mononuclear phagocyte system uptake, stability and biodistribution. Additionally, management of the above mentioned disorders require regular and intrusive therapy making non-invasive routes preferable in comparison to invasive routes like parenteral. The nasal route is garnering focus in delivery of NBTs to the brain in the management of several CNS disorders due to the associated merits such as non-invasiveness, possibility of chronic delivery, improved patient compliance, avoidance of hepatic and gastrointestinal metabolism as well as ability to bypass the BBB. Hence in recent times, this route has been sought by the reserachers as an alternative to parenteral therapy for the delivery of several NBTs. This review shall focus on an array of NBTs delivered through nasal route, their challenges, applications and opportunities. The novel delivery systems for incorporating NBTs; their targeting strategies shall be critically reviewed. The challenges towards regulatory approvals and commercialization shall also be discussed at large. Comparison of learnings derived from the success and barriers in nasal delivery of NBTs will help in identification of futuristic opportunities for their translation from bench to bedside.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics
    Mukai, Hidefumi
    Ogawa, Koki
    Kato, Naoya
    Kawakami, Shigeru
    DRUG METABOLISM AND PHARMACOKINETICS, 2022, 44
  • [32] Current trends in delivery of non-viral nucleic acid-based therapeutics for improved efficacy
    Avci-Adali, Meltem
    Santos, Helder A.
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 185
  • [33] Prospects for nucleic acid-based therapeutics against hepatitis C virus
    Lee, Chang Ho
    Kim, Ji Hyun
    Lee, Seong-Wook
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (47) : 8949 - 8962
  • [34] Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic
    van den Berg, Annette I. S.
    Yun, Chae-Ok
    Schiffelers, Raymond M.
    Hennink, Wim E.
    JOURNAL OF CONTROLLED RELEASE, 2021, 331 : 121 - 141
  • [35] Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor
    Xiao, Yao
    Shi, Kun
    Qu, Ying
    Chu, Bingyang
    Qian, Zhiyong
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 12 : 1 - 18
  • [36] Addressing the in vivo delivery of nucleic-acid nanostructure therapeutics
    Alexander S.
    Moghadam M.G.
    Rothenbroker M.
    Y.T. Chou L.
    Advanced Drug Delivery Reviews, 2023, 199
  • [37] Lipid-based nucleic acid therapeutics with in vivo efficacy
    Abu Sufian, Md.
    Ilies, Marc A.
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2023, 15 (02)
  • [38] Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?
    O'Driscoll, Caitriona M.
    Bernkop-Schnuerch, Andreas
    Friedl, Julian D.
    Preat, Veronique
    Jannin, Vincent
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 133 : 190 - 204
  • [39] The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery
    Shorter, Susan A.
    Gollings, Alexander S.
    Gorringe-Pattrick, Monique A. M.
    Coakley, J. Emma
    Dyer, Paul D. R.
    Richardson, Simon C. W.
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (05) : 685 - 696
  • [40] Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies
    Karlsson, Johan
    Luly, Kathryn M.
    Tzeng, Stephany Y.
    Green, Jordan J.
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 179